To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.
Foreword Murat Emre
Murat Emre was born in 1956, in Eregli, Turkey. After studying medicine at the Istanbul Faculty of Medicine he was trained in
neuroscience and clinical neurology at the University of Zürich. He then worked in the fields of neurorehabilitation and clinical research
in Switzerland for several years. He trained in movement disorders with David Marsden at the Queen Square National Hospital for
Nervous Diseases, London, and in behavioural neurology with Marsel Mesulam at the Beth Israel Hospital and Harvard Medical School.
In 1996, he was assigned as Professor of Neurology at the Istanbul Faculty of Medicine, Department of Neurology, where he started
the Behavioural Neurology and Movement Disorders Unit. His research interests are in Parkinson’s disease and related disorders, in
particular cognitive aspects of the disease, Alzheimer’s disease and related dementias. He has authored or co-authored several hundred
articles and book chapters, and he has been the editor of several books.
W elcome to the latest edition of European Neurological Review. This issue features a number of topical articles
that have been chosen for their assessment of current practices and research that directly affect neurologists
and other practitioners involved in the care of patients with neurological illness.
The number of people with dementia is steadily increasing and there is an urgent need to plan for the future to ensure
that the right care and support is available. In an editorial, Jean Georges discusses the findings and implications of a new
Alzheimer Europe report, ‘European Dementia Monitor 2017: comparing and benchmarking national dementia strategies
and policies’. We also feature an expert interview with Clive Ballard on the subject of psychotic episodes in Alzheimer’s
disease (AD), a common occurrence that is associated with more rapid cognitive and functional deterioration.
The importance of B cells is increasingly being recognised in the pathophysiology of multiple sclerosis (MS). Nikolaos
Grigoriadis reviews the novel approach of targeting of both T and B cells in MS, with a focus on the recently developed
therapy, alemtuzumab. Also on the subject of MS, in an expert interview, Gavin Giovannoni discusses cladribine, the first
oral short-course treatment to provide efficacy across key measures of disease activity in adult patients with highly active
relapsing MS, which is now available in Europe.
Following the recent 18th Congress of the International Headache Society in Vancouver, Canada in September 2017,
Rothrock and Reuter present two expert perspectives on the use of preventative therapies for migraine. In addition,
Cortelli et al. provide an overview of the use of triptans in the treatment of acute migraine.
Psychotic symptoms occur in almost half of patients with Parkinson’s disease (PD) and, in addition to the disruption they
cause to the lives of patients and their caregivers, have consistently been shown to be associated with poor outcomes.
Current guidelines include recommendations for managing symptoms of psychosis in patients with PD. In two original
research articles, Keziah Cook et al. describe the prevalence patterns of PD psychosis and also the patterns of care and
treatment for the condition across the European Union (EU).
Finally, Jacques De Reuck presents an original study describing the imaging of cerebrovascular lesions in Pick complex
diseases with 7.0-tesla magnetic resonance imaging. The Pick complex diseases have the common feature of a low
incidence of real cerebrovascular lesions, a useful diagnostic finding.
European Neurological Review would like to thank all expert authors who contributed to this edition. Special thanks
go to our Editorial Board for their continuing support and guidance. We are also grateful to all our media partners and
organisations for their ongoing support. We trust that you will find this edition of European Neurological Review useful
and interesting. q
TOU CH MED ICA L MEDIA